ClinicalTrials.gg
CompletedNCT06258265Updated Jul 11, 2024

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

A Phase 1 interventional study of TAK-279 and TAK-279 Placebo in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Takeda · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main aim of this study is to find out how more than one dose of TAK-279 changes the heart-rate corrected QT (QTc) interval of healthy adults. A QTc interval is a measurement on an electrocardiogram (ECG) and shows the time when the heart contracts until it finishes relaxing. Other aims are to learn about the effect of several doses of TAK-279 on other ECG measurements of healthy adults, how the body of a healthy adult processes TAK-279 and moxifloxacin (pharmacokinetics), and to learn about the side effects of TAK-279 and how well it is tolerated when given to healthy adults.

The participants will be given TAK-279 and moxifloxacin or a placebo for 7 days.

During the study, participants will need to stay at the clinic for 10 days.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the study procedures in the form (ICF) and be willing and able to comply with the protocol.
  2. Healthy, adult, male or female, 18-55 years of age, inclusive, at the screening visit.
  3. Female participants of and non-sterilized male participants must follow protocol specified guidance as described in protocol.
  4. Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first baseline cardiodynamic measurement (Day -1) based on participant self-reporting.
  5. greater than or equal to (>=) 18.0 and less than or equal to (\<=) 32.0 kilograms per meter square (kg/m\^2) at the screening visit.
  6. Medically healthy with no medical history, physical examination, laboratory profiles, vital signs, and (ECGs), as deemed by the Investigator or designee, including the following:

    • Supine blood pressure is >=90/40 millimeter of mercury (mmHg) and \<=140/90 mmHg at the screening visit.
    • Supine pulse rate is >=40 beats per minute (bpm) and \<=99 bpm at the screening visit.
    • using Fridericia's formula (QTcF) interval is \<=450 milliseconds (msec) (males) and \<=460 msec (female) at the screening visit.
    • QRS interval \<=110 msec at the screening visit (if >110 msec, result will be confirmed by a manual over read).
    • PR interval \<=220 msec at the screening visit.
    • >=80 milliliter per minute per 1.73 meter square (mL/min/1.73m\^2) at the screening visit.
    • Liver function tests including (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total \<= (ULN) at the screening visit and at check-in.
    • Creatine phosphokinase (CPK) \<=ULN at the screening visit and at check-in.
    • Amylase and lipase \<=ULN at the screening visit and at check-in.
    • No clinically significant hypokalemia, hypomagnesemia, or other electrolyte abnormalities at the screening visit.
  7. Able to swallow multiple capsules.

Exclusion criteria

Exclusion Criteria:

  1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. History or presence of medical or psychiatric condition or disease in the opinion of the Investigator or designee.
  3. History of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
  4. Has a history of any of the following:

    • Active infection or febrile illness within 7 days prior to first baseline cardiodynamic measurement (Day -1), as assessed by the Investigator or designee.
    • Symptoms suggestive of systemic or invasive infection requiring hospitalization or treatment within 8 weeks prior to first baseline cardiodynamic measurement (Day -1).
    • Chronic or recurrent bacterial disease, including but not limited to chronic pyelonephritis or cystitis, chronic bronchitis/pneumonitis, osteomyelitis, or chronic skin ulcerations/infections or fungal infections (except superficial nailbed mycosis).
    • An infected joint prosthesis unless that prosthesis has been removed or replaced greater than 60 days prior to first baseline cardiodynamic measurement (Day -1).
    • Opportunistic infections (eg, Pneumocystis jirovecii pneumonia, histoplasmosis, coccidiomycosis).
    • Cancer or lymphoproliferative disease, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.
    • Known or suspected condition/illness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency; splenectomy.
    • Liver, kidney, heart, or other solid organ transplant.
    • Myasthenia gravis.
    • Peripheral neuropathy.
  5. Has history or presence of alcoholism and/or drug abuse within the past 2 years prior to first baseline cardiodynamic measurement (Day -1), as determined by the Investigator or designee.
  6. History or presence of or idiosyncratic reaction to the study drugs.
  7. Allergy to band aids, adhesive dressing, or medical tape.
  8. History or presence of any of the following, deemed clinically relevant by the Investigator or designee at the screening visit or at check-in:

    • Cardiac disease; arrhythmias, presyncope, or syncopal episodes; heart failure, heart disease or risk factors for torsades de pointes (including long syndrome or family history of long QT syndrome).
    • Sick sinus syndrome, second or third degree atrioventricular block, myocardial infarction, pulmonary congestion, history of cardiac arrhythmia, prolonged QTcF interval, or conduction abnormalities.
    • Ischemic heart disease, poorly controlled hypertension, or other cardiovascular disorder
    • T wave flattening or other abnormalities which in the opinion of the Investigator or designee may interfere with the analysis of QT intervals.
    • A family history of sudden cardiac death.
  9. Female participant with a positive pregnancy test at the screening visit or at check-in or who is breastfeeding and/or lactating.
  10. Positive urine drug or alcohol results at the screening visit or at check-in.
  11. Positive Coronavirus disease 2019 (COVID-19) result at check-in.
  12. Unable to refrain from or anticipates the use of:

    • Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements, including any cytochrome P450 (CYP)3A4 inhibitors, beginning 14 days prior to the first baseline cardiodynamic measurement (Day -1).
    • Any drugs known to be inducers of enzymes and/or P-glycoprotein (P-gp), including St. John's Wort, for 28 days prior to the first baseline cardiodynamic measurement (Day -1). Appropriate sources (eg, Flockhart Table™) including the product label for moxifloxacin will be consulted to confirm lack of pharmacokinetic (PK)/pharmacodynamic interaction with the study drugs.
    • Any drugs known to prolong the QT/QTc interval for 28 days or 5 half-lives (whichever is longer) prior to the first baseline cardiodynamic measurement (Day -1).
  13. Has been on a diet incompatible with the on study diet, in the opinion of the Investigator or designee, within the 30 days prior to first baseline cardiodynamic measurement (Day -1) and throughout the study.
  14. Has made a donation of blood or had significant blood loss within 56 days prior to first baseline cardiodynamic measurement (Day -1).
  15. Has made a plasma donation within 7 days prior first baseline cardiodynamic measurement (Day -1).
  16. Participated in another clinical study within 30 days prior to first baseline cardiodynamic measurement (Day -1). The 30-day window will be derived from the date of the last dosing in the previous study to Day -1 of the current study.
  17. Herpes infections:

    • Has active herpes virus infection, including herpes zoster or herpes simplex 1 and 2 (demonstrated on physical examination and/or medical history) at the screening visit or check-in.
    • Has history of serious herpetic infection that includes any episode of disseminated disease, multidermatomal herpes zoster virus, herpes encephalitis, ophthalmic herpes, or recurrent herpes zoster (defined as 2 episodes within 2 years).
  18. Positive results for non-herpetic viral diseases at the screening visit:

    • virus (HCV) antibody and a positive confirmatory test result for HCV ribonucleic acid (RNA; nucleic acid test or polymerase chain reaction [PCR]).
    • Hepatitic B surface antigen (+), hepatitis B virus deoxyribonucleic acid (DNA), or hepatitis B core antibody (HBcAb+) with positive hepatitis B virus DNA.
    • (HIV).
  19. Positive results for tuberculosis (TB) at the screening visit or has any of the following:

    • Has history of active TB infection, regardless of treatment status.
    • Has signs or symptoms of active TB (including but not limited to chronic fever, chronic productive cough, night sweats, or weight loss) as judged by the Investigator or designee.
    • Has evidence of latent tuberculosis infection (LTBI) as evidenced by a positive Quantiferon TB Gold (QFT) result or 2 indeterminant QFT results and does not have documentation of appropriate LTBI prophylaxis. Participant remains eligible if he or she can provide documentation of prior and complete treatment for LTBI (appropriate in duration and type per current local country guidelines).
    • Has had any imaging study prior to the screening visit, including x ray, chest computed tomography, magnetic resonance imaging, or other chest imaging suggesting evidence of current active or a history of active TB.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Cohort 1, Therapeutic Dose Cohort: TAK-279 + TAK-279 Placebo + Moxifloxacin Placebo

    Participants will receive TAK-279 Dose 1 and matching placebo, capsules, once daily (QD) on Days 1 to 7 with moxifloxacin matching placebo, capsule, once on Days 1 and 8.

    Drug: TAK-279 · Drug: TAK-279 Placebo · Drug: Moxifloxacin Placebo

  • Experimental
    Cohort 2, Supratherapeutic Dose Cohort: TAK-279 + Moxifloxacin Placebo

    Participants will receive TAK-279 Dose 2, capsules, QD on Days 1 to 7 with moxifloxacin matching placebo, capsule once on Days 1 and 8.

    Drug: TAK-279 · Drug: Moxifloxacin Placebo

  • Experimental
    Cohort 3A, Control Cohort: Moxifloxacin + TAK-279 Placebo + Moxifloxacin Placebo

    Participants will receive moxifloxacin Dose 3, over-encapsulated tablet on Day 1 with TAK-279 matching placebo, QD on Days 1 to 7 and moxifloxacin placebo, capsule, once on Day 8.

    Drug: TAK-279 Placebo · Drug: Moxifloxacin · Drug: Moxifloxacin Placebo

  • Experimental
    Cohort 3B, Control Cohort: TAK-279 Placebo + Moxifloxacin Placebo + Moxifloxacin

    Participants will receive moxifloxacin matching placebo, capsule on Day 1 with TAK-279 matching placebo, QD on Days 1 to 7 and moxifloxacin Dose 3, over-encapsulated tablet, once on Day 8.

    Drug: TAK-279 Placebo · Drug: Moxifloxacin · Drug: Moxifloxacin Placebo

Interventions

  • TAK-279 capsule.

  • DrugTAK-279 Placebo

    TAK-279 matching placebo capsule.

  • Moxifloxacin over-encapsulated tablet.

  • DrugMoxifloxacin Placebo

    Moxifloxacin matching placebo capsule.

06

What researchers measure

Primary outcomes

  1. Placebo-corrected Change From Baseline in QTc Interval (ΔΔQTc) for TAK-279

    Placebo-corrected QTc interval will be measured by continuous ECG recordings.

    Time frame: Baseline, Days 1, 7, and 8

Secondary outcomes

  1. Change From Baseline in Heart Rate (HR [ΔHR]) for TAK-279

    HR will be measured by continuous ECG recordings.

    Time frame: Baseline, Days 1, 7, and 8

  2. Change From Baseline in QTc (ΔQTc) Interval for TAK-279

    QTc interval will be measured by continuous ECG recordings.

    Time frame: Baseline, Days 1, 7, and 8

  3. Change From Baseline in PR Interval (ΔPR) for TAK-279

    PR interval will be measured by continuous ECG recordings.

    Time frame: Baseline, Days 1, 7, and 8

  4. Change From Baseline in QRS Interval (ΔQRS) for TAK-279

    QRS interval will be measured by continuous ECG recordings.

    Time frame: Baseline, Days 1, 7, and 8

  5. Placebo-corrected Change From Baseline in HR (ΔΔHR) for TAK-279

    Placebo-corrected HR will be measured by continuous ECG recordings.

    Time frame: Baseline, Days 1, 7, and 8

  6. Placebo-corrected Change From Baseline in ΔPR (ΔΔPR) for TAK-279

    Placebo-corrected PR will be measured by continuous ECG recordings.

    Time frame: Baseline, Days 1, 7, and 8

  7. Placebo-corrected Change From Baseline in QRS (ΔΔQRS) for TAK-279

    Placebo-corrected QRS interval will be measured by continuous ECG recordings.

    Time frame: Baseline, Days 1, 7, and 8

  8. Number of Participants With Categorical Outliers for HR, PR, QRS, and QTc for TAK-279

    HR, PR, QRS, and QTc will be measured by continuous ECG recordings.

    Time frame: Baseline, Days 1, 7, and 8

  9. Change From Baseline in Electrocardiogram (ECG) Morphology for TAK-279

    ECG morphological analyses will be performed using the ECG waveform interpretation as defined by the central ECG laboratory's cardiologist.

    Time frame: Baseline, Days 1, 7, and 8

  10. Placebo-corrected Change From Baseline in QTc Interval (ΔΔQTc) for Moxifloxacin

    Placebo-corrected QTc interval will be measured by continuous ECG recordings.

    Time frame: Baseline, Days 1, 7, and 8

  11. Maximum Observed Plasma Concentration (Cmax) of TAK-279 and Moxifloxacin

    Time frame: Days 1 (TAK-279 and Moxifloxacin) and 7 (TAK-279): Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post-dose; Day 8 (Moxifloxacin): 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post-dose

  12. Time to Reach Cmax (tmax) of TAK-279 and Moxifloxacin

    Time frame: Days 1 (TAK-279 and Moxifloxacin) and 7 (TAK-279): Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post-dose; Day 8 (Moxifloxacin): 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post-dose

  13. Area Under the Plasma Concentration-Time Curve During a Dosing Interval (tau) at Steady State (AUCτ) of TAK-279

    Time frame: Days 1 and 7: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post-dose

  14. Area Under the Plasma Concentration-Time Curve From Time Zero to 24 hours (AUC0-24) of Moxifloxacin

    Time frame: Day 1: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post-dose; Day 8: 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post-dose

  15. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)

    Time frame: Baseline up to Day 22

  16. Number of Participants With Markedly Abnormal Values (MAVs) in Vital signs Parameters

    Vital signs assessment will include blood pressure, pulse rate, respiratory rate, and oral temperature parameters.

    Time frame: Baseline up to Day 9

  17. Number of Participants With MAVs in 12-lead ECGs Measurement

    ECGs will be performed with participants in a supine position.

    Time frame: Baseline up to Day 9

  18. Number of Participants With MAVs in Clinical Laboratory Assessments

    Clinical laboratory assessment will include includes hematology, chemistry, and urinalysis parameters.

    Time frame: Baseline up to Day 9

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Jun 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 14, 2024
StartActual
Apr 29, 2024
Primary completionActual
Jun 25, 2024
CompletionActual
Jul 9, 2024
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06258265
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Apr 29, 2024
Primary completion
Jun 25, 2024
Completion
Jul 9, 2024
Last update
Jul 11, 2024

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zasocitinib · Moxifloxacin

Start the discussion